Trevi Therapeutics
TRVI | NASDAQ
$13.29
-$0.36 (-2.64%)
At close: Nov 16, 2026, 4:00 PM ET
$13.29
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:38 PM ET
Trevi Therapeutics Company Profile
Company profile explainedCompany Profile
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations. Established in 2011, the company maintains its corporate headquarters in New Haven, Connecticut.
Key Executives
| Name | Position |
|---|---|
| Jennifer L. Good | Co-Founder, Chief Executive Officer, President & Director |
| David C. Hastings | Chief Financial Officer & Principal Financial Officer |
| Christopher Galletta | Controller & Chief Accounting Officer |
| Farrell Simon | Chief Commercial Officer |
| James V. Cassella | Chief Development Officer |
| Katie McManus | Communications Manager |
| Thomas R. Sciascia | Co-Founder & Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 27, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Sep 17, 2026 | 4 | Filing |
| Aug 06, 2026 | S-8 | Filing |
| Aug 06, 2026 | 10-Q | Quarterly Report |
| Aug 06, 2026 | 8-K | Current Report |
| Aug 06, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Jun 04, 2026 | 4 | Filing |
| Jun 04, 2026 | 8-K | Current Report |
| Jun 04, 2026 | 4 | Filing |
| Jun 04, 2026 | 4 | Filing |
Trevi Therapeutics
| Country | United States |
| IPO Date | May 7, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 34 |
| CEO | Jennifer L. Good |
Contact Details
195 Church Street New Haven,
Connecticut 06510 United States
Stock Details
| Ticker Symbol | TRVI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001563880 |
| CUSIP Number | 89532M101 |
| ISIN Number | US89532M1018 |
| SIC Code | 2834 |
Recent News
- 7 days ago / seekingalpha.comTrevi Therapeutics, Inc. (TRVI) Q3 2026 Earnings Call Transcript
- 7 days ago / marketbeat.comWhat Trevi Therapeutics (TRVI) Said on Its Q3 Earnings Call
- 7 days ago / globenewswire.comTrevi Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates
- 14 days ago / globenewswire.comTrevi Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 9, 2026
- 21 days ago / globenewswire.comTrevi Therapeutics to Participate in Stifel's 2026 Healthcare Conference
- 1 month ago / globenewswire.comTrevi Therapeutics Announces Oral Presentation Accepted at the CHEST 2026 Annual Meeting
- 2 months ago / seekingalpha.comTrevi Therapeutics, Inc. (TRVI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 3 months ago / globenewswire.comTrevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026
- 3 months ago / seekingalpha.comTrevi Therapeutics: A Specialty Beachhead Creates A Chronic Cough Platform
- 3 months ago / marketbeat.comTrevi Therapeutics Q2 Earnings Call Highlights
Add to Watchlist
Select watchlists to add or remove TRVI